Articles

ANVISA Clinical Trial Regulations: What Foreign Pharma Must Know in 2025

Learn essential insights on ANVISA's clinical trial regulations for 2025, crucial for foreign pharmaceutical companies navigating drug approvals in Brazil.

Decentralized Clinical Trials in LATAM: Growth, Challenges & Regulatory Insights

This article delves into the rise of decentralized clinical trials in LATAM, highlighting key growth factors, challenges faced, and essential regulatory insights.

COFEPRIS Approval Pathway: Insights on Novel Immunotherapies for Advanced Melanoma

This article delves into the COFEPRIS approval process for innovative immunotherapies targeting advanced melanoma, highlighting key insights and drug developments.

Biosimilars Growth in Brazil: Market Potential Post-ANVISA Regulatory Updates

This article delves into the market potential for biosimilars in Brazil following recent ANVISA regulatory updates, highlighting Infliximab's role in treating autoimmune conditions.

ANVISA Regulatory Changes: Impact on Fast-Track Approvals for Oncology Drugs

This article examines how recent ANVISA regulatory changes affect the fast-track approval process for oncology drugs, enhancing patient access to treatments.

HIV Treatment Clinical Trials Africa: Long-Acting Injectables & AMA Pathways

This article delves into HIV treatment clinical trials in Africa, highlighting long-acting injectables and the AMA pathways for enhanced patient care.

Cancer Immunotherapies UAE: Regulatory and Access Insights 2025

This article provides essential insights into the regulatory landscape and access to cancer immunotherapies in the UAE, focusing on key drugs and future trends.

Mounjaro FDA Approval Obesity: Eli Lilly's Tirzepatide Awaits

Eli Lilly's Mounjaro (tirzepatide) is poised for a significant label expansion, seeking FDA approval for obesity and cardiovascular risk reduction. This potential approval could reshape the weight management and cardiovascular health markets.

Osimertinib FDA Approval Expands Early-Stage NSCLC Treatment

The FDA has approved osimertinib (Tagrisso) for adjuvant treatment of early-stage NSCLC, marking a milestone for AstraZeneca and expanding treatment options. Learn about the clinical data, market impact, and investment implications.

Bispecific Antibodies in Hematological Malignancies: Teclistamab, Mosunetuzumab & Epcoritamab FDA Review

This article delves into the FDA review of bispecific antibodies teclistamab, mosunetuzumab, and epcoritamab for hematological malignancies.

Alzheimer's Clinical Trial Failures: Insights from Semaglutide & Posdinemab FDA Trials

This article delves into the recent failures of Alzheimer's clinical trials involving Semaglutide and Posdinemab, highlighting key insights and future directions.

FDA Approval OncoBlast: Market Impact for Advanced Melanoma

This article analyzes the FDA approval of OncoBlast for advanced melanoma, highlighting its market impact and benefits for patients and healthcare providers.

FDA Accelerated Approvals Oncology: 2026 Policy Review & Zongertinib Case

This article delves into the FDA's 2026 policy review on accelerated approvals in oncology, focusing on the case of Zongertinib for lung cancer therapy.

KRAS G12C Inhibitors NSCLC: Market Analysis of Sotorasib & Adagrasib

This article delves into the market dynamics of KRAS G12C inhibitors, Sotorasib and Adagrasib, highlighting their roles in non-small cell lung cancer treatment.

FDA Approval Elranatamab: Efficacy, Safety & Market Impact in RRMM

Elranatamab has gained FDA approval for relapsed/refractory multiple myeloma, showcasing promising efficacy and safety, and is set to impact the market significantly.

CAR-T Therapy Clinical Trials: Insights from ASCO 2026 and FDA Approval Implications

Discover the latest insights on CAR-T therapy from ASCO 2026 and understand the potential implications of FDA approval for innovative cancer treatments.

FDA Guidance on Decentralized Clinical Trials: What You Need to Know

This article covers essential FDA guidance on decentralized clinical trials, focusing on their impact on drug development and patient engagement.

FDA Accelerated Approvals Oncology: 2026 Review of Benefit-Risk and Confirmatory Trials

This article reviews the FDA's Accelerated Approvals in Oncology, highlighting the benefit-risk balance and the importance of confirmatory trials for cancer treatments.

SFDA Accelerated Approval Oncology: Impact on Innovative Drugs in Saudi Arabia

The SFDA's Accelerated Approval program significantly impacts the availability of innovative oncology drugs, such as Keytruda, for cancer patients in Saudi Arabia.

FDA Accelerated Approval Pathway: Impact on Oncology Drug Development & Market Access 2026

This article examines the FDA Accelerated Approval Pathway and its significant influence on the development and market access of oncology drugs by 2026.